Monte Rosa Therapeutics, Inc. (GLUE) stock
GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07−0.09 (-0.98%)
Close on Nov 17, 2026Market cap $773.79MP/E –Yield –
Monte Rosa Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
No total debt figures for Monte Rosa Therapeutics
Monte Rosa Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?